SI-BONE's Quarter Will Test Whether Revenue Growth Can Narrow the Path to Profitability

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

SIBN reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to actual earnings.

Historical price behavior around SIBN earnings reveals significant volatility with a strong upward bias on Day +1. The average absolute Day 0 move of 2.43% is relatively modest, reflecting pre-announcement positioning, but Day +1 shows an average absolute move of 10.70%—more than four times larger—as the market digests actual results.

The most striking pattern is the dramatic Day +1 reactions following recent reports. In the past four quarters, SIBN delivered Day +1 gains of +19.72% (May 2026), +16.20% (November 2025), and +15.44% (May 2025), demonstrating that strong earnings beats have translated into substantial price appreciation. Even when Day 0 showed weakness—such as the -5.38% move in May 2026—the following session reversed sharply higher as investors absorbed the better-than-expected results.

The average Day +1 range of 12.24% indicates substantial intraday volatility regardless of direction, suggesting options traders and active investors should prepare for significant price swings. Given SIBN's consistent pattern of beating estimates by 30-70% and the historical tendency for Day +1 to deliver double-digit percentage moves, investors should anticipate potentially outsized post-earnings volatility for this release.

Part 2.2: Options Market Expected Move

The options market is pricing in a 0.00% expected move for the November expiration, which appears to be incomplete or unavailable data. Based on historical earnings behavior showing an average Day +1 move of 10.70% and recent quarters delivering moves as large as 19.72%, options traders should expect significantly higher implied volatility closer to the earnings date as the market prices in SIBN's characteristic post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on SIBN is overwhelmingly bullish, with the stock earning an average recommendation of 4.70 out of 5.0—firmly in strong buy territory. The consensus is supported by 8 strong buy ratings, 1 moderate buy, and just 1 hold, with zero sell ratings across the 10 analysts covering the stock. This represents one of the most concentrated bullish views in the medical device sector.

The mean price target of $25.44 implies approximately 19.8% upside from the current price of $21.23, with the range of estimates spanning from a low of $20.00 to a high of $32.00. The wide spread in targets—from essentially flat to over 50% upside—reflects differing views on the pace of commercialization for SIBN's product pipeline and the company's path to profitability.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.70. This stability suggests analysts are maintaining conviction in their bullish thesis despite the recent packaging recall headlines, viewing the quality control issue as a manageable operational matter rather than a fundamental threat to the growth story.

The consensus view appears anchored on SIBN's ability to sustain gross margins near the upper end of guidance while successfully launching 1-2 new products annually. However, some analysts have expressed caution that the company's decision to invest heavily in surgical capacity and R&D ahead of full commercialization creates execution risk, particularly if early adoption proves slower than expected or if the recall impacts near-term sales momentum.

Part 4: Technical Picture

SIBN enters earnings with strong technical momentum across all timeframes, as the Barchart Technical Opinion currently shows a 100% Buy signal—up from 100% Buy last week and 40% Buy last month. This dramatic strengthening over the past month reflects accelerating bullish momentum as the stock has broken out to new highs.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings release
• Medium-term (100% Buy): Strong buy signal confirms the intermediate trend remains firmly positive with no signs of exhaustion
• Long-term (100% Buy): Maximum long-term buy rating suggests the broader uptrend is well-established and sustainable

Trend Characteristics: The combination of Maximum strength and Average direction indicates SIBN is in a powerful uptrend with typical directional consistency, suggesting momentum is robust but not yet reaching extreme or unsustainable levels that might signal a reversal.

The stock is trading at $21.23, positioned above all major moving averages—the 10-day ($21.23), 20-day ($20.39), 50-day ($19.41), 100-day ($18.38), and 200-day ($16.40)—though it sits just slightly below the 5-day average of $21.64. This alignment represents a textbook bullish setup, with each successively longer-term moving average providing support below the current price.

The 29.5% gain above the 200-day moving average demonstrates the strength of the long-term uptrend, while the stock's position above all key support levels suggests technical buyers remain in control. The only minor caution is the slight pullback below the 5-day average, which could indicate short-term profit-taking ahead of the earnings event. Overall, the technical setup is highly supportive heading into earnings, with strong momentum, clean uptrend structure, and multiple layers of support positioned below current levels to cushion any disappointment. However, given the stock's 50%+ gain over the past year and the recent recall headlines, any earnings miss or cautious guidance could trigger profit-taking from an extended technical position.